Skip to content

Abdominal Binding in Chronic Obstructive Pulmonary Disease

Abdominal Binding: a Novel Intervention to Relieve Dyspnea and Improve Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01852006
Enrollment
20
Registered
2013-05-13
Start date
2014-01-31
Completion date
2015-05-31
Last updated
2015-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Dyspnea

Brief summary

Conventional approaches to relieve dyspnea (respiratory discomfort) in chronic obstructive pulmonary disease (COPD) have focused on improving respiratory motor drive (e.g., hyperoxia) and/or dynamic respiratory mechanics (e.g., bronchodilators). Although these approaches yield meaningful symptom improvements there remains many COPD patients incapacitated by dyspnea. Accumulating evidence suggests that abdominal binding (AB) is a potentially novel method of improving respiratory muscle function and, by extension, dyspnea and exercise tolerance in COPD. Thus, the purpose of this randomized, cross-over study is to test the hypothesis that AB improves exertional dyspnea and exercise tolerance in symptomatic patients with COPD by improving dynamic respiratory muscle function. To this end, the investigators will examine the effects of AB on detailed assessments of baseline pulmonary function (spirometry, plethysmography), dyspnea (sensory intensity & affective responses), neural respiratory drive (diaphragm EMG), contractile respiratory muscle function (esophageal, gastric & transdiaphragmatic pressures), ventilation, breathing pattern and cardiometabolic function during symptom-limited constant load cycle exercise (75% Wmax) in 20 patients with GOLD stage II/III COPD.

Interventions

Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.

Sponsors

McGill University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or Female * Aged ≥40 years * Ambulatory * Cigarette smoking history ≥15 pack years * No change in medication dosage or frequency of administration, with no exacerbations or hospitalization in the preceding 6 weeks. * Post-bronchodilator Forced Expiratory Volume in 1 second between 30-80% predicted * Post-bronchodilator Forced Expiratory Volume in 1 second/forced vital capacity ratio of \<70%

Exclusion criteria

* Presence of active cardiopulmonary disease other than COPD * Use of domiciliary oxygen * Exercise-induced arterial blood oxyhemoglobin desaturation to \<80% on room air. * Body Mass Index \<18.5 or ≥35 kg/m2. * Allergy to latex * Allergy to lidocaine or its caine derivates.

Design outcomes

Primary

MeasureTime frame
Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime during exercisePatients will be followed until all study visits are complete, an expected average of 2 weeks

Secondary

MeasureTime frame
Exercise Endurance Time (EET)Patients will be followed until all study visits are complete, an expected average of 2 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026